ESMO Open

OCT 13, 2026 · JOURNAL ARTICLE

“Our patients deserve better”—roadblocks to optimal care in biliary malignancies

ESMO Open

Biliary tract cancers (BTCs) are associated with poor outcomes, with many patients never receiving any cancer-directed treatment. Population-based registries from England, France,

SEP 24, 2026 · JOURNAL ARTICLE

Atezolizumab plus pertuzumab, trastuzumab, and chemotherapy in HER2-positive early breast cancer: final results of the phase III IMpassion050 trial

ESMO Open

BACKGROUND: The IMpassion050 (NCT03726879) primary analysis showed similar pathologic complete response (pCR) rates with/without the addition of neoadjuvant atezolizumab to pertuzu

SEP 22, 2026 · JOURNAL ARTICLE

Pattern and quality of care for rare head and neck cancers treated in expert centres: the experience of the registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)

ESMO Open

Background Rare head and neck cancers (HNCs), including sinonasal cancers (SNC), nasopharyngeal cancers (NPC), and salivary gland cancers (SGC), are biologically diverse and infreq

SEP 15, 2026 · JOURNAL ARTICLE

Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting

ESMO Open

BACKGROUND: Real-world data analyses show durable benefits with elacestrant, with or without prior treatment with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i). This cohort focus

SEP 9, 2026 · REVIEW

Randomised phase III trials of cancer prevention drugs: a systematic review and prediction of trial success

ESMO Open

A rigorous systematic review of 92 phase III RCTs over 45 years with 659,904 participants, using prespecified definitions of success and multivariable logistic regression to identify predictors of trial outcomes in cancer prevention.

AUG 7, 2026 · JOURNAL ARTICLE

HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility

ESMO Open

Meta-analyses demonstrate independent prognostic and predictive associations of HER2DX scores with survival and pathological response beyond standard factors, supported by translational validation and prospective trial data.